GO:0004014 adenosylmethionine decarboxylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004014 describes the catalytic activity that converts S-adenosyl-L-methionine (SAM) into S-adenosylmethioninamine (decarboxylated SAM) and CO2, a committed step in polyamine biosynthesis.
• The enzyme adenosylmethionine decarboxylase (AMD1) is a key regulator of polyamine homeostasis and is essential for cell growth and proliferation.
• AMD1 is a validated target in cancer and other diseases, with elevated activity linked to tumor progression and neurodegenerative conditions [4,8].
• Structural and mechanistic studies reveal that AMD1 uses a pyruvoyl cofactor and undergoes autocatalytic processing for activation.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of AMD1 function in health and disease.
• Advanced methods such as metabolic flux analysis, enzyme assays, and CRISPR screening are used to study AMD1 and its role in polyamine metabolism [2,4].
Description
Adenosylmethionine decarboxylase activity (GO:0004014) is a molecular function that catalyzes the decarboxylation of S-adenosyl-L-methionine (SAM) to produce S-adenosylmethioninamine (also known as decarboxylated SAM) and carbon dioxide. This reaction is a critical step in the biosynthesis of polyamines, which are small polycationic molecules essential for cell growth, proliferation, and differentiation. The enzyme responsible, adenosylmethionine decarboxylase (AMD1), is highly regulated and its activity is often altered in cancer and other diseases [4,6]. Understanding this activity is therefore fundamental for researchers studying polyamine metabolism, cancer biology, and potential therapeutic interventions [1,3].
adenosylmethionine decarboxylase activity At A Glance
| GO ID | GO:0004014 |
|---|---|
| GO term | adenosylmethionine decarboxylase activity |
| Ontology | molecular_function |
| Synonym | S-adenosyl-L-methionine decarboxylase activity; adenosyl methionine decarboxylase activity; S-adenosylmethionine decarboxylase activity |
| Major function | Catalyzes the decarboxylation of S-adenosyl-L-methionine to S-adenosylmethioninamine and CO2, a key step in polyamine biosynthesis. |
| Reaction | S-adenosyl-L-methionine + H+ = S-adenosylmethioninamine + CO2. |
| Cofactor | Pyruvoyl group (formed by autocatalytic processing of the proenzyme). |
| Subcellular location | Cytosol (in mammals). |
| Pathway | Polyamine biosynthesis (spermidine and spermine synthesis). |
What Is GO:0004014?
According to the Gene Ontology, adenosylmethionine decarboxylase activity (GO:0004014) is defined as the catalysis of the reaction: S-adenosyl-L-methionine + H+ = S-adenosylmethioninamine + CO2. In simpler terms, it is the enzyme activity that removes a carboxyl group from SAM, yielding decarboxylated SAM, which serves as an aminopropyl donor for polyamine synthesis [1,3].
Why Is adenosylmethionine decarboxylase activity Important in Cell Biology?
Adenosylmethionine decarboxylase activity is essential for polyamine biosynthesis, which regulates fundamental cellular processes including growth, proliferation, and apoptosis. Dysregulation of this activity is implicated in various diseases, particularly cancer, where elevated polyamine levels support rapid cell division. Moreover, AMD1 is a target for therapeutic intervention, with inhibitors being developed for cancer treatment. Therefore, studying this activity provides insights into basic cell biology and offers potential avenues for disease therapy [1,4].
• Critical for polyamine biosynthesis, which is required for cell growth and proliferation.
• Elevated activity is observed in many cancers, making it a potential biomarker and therapeutic target.
• Altered activity has been linked to neurodegenerative diseases such as Alzheimer's disease.
• AMD1 is regulated at multiple levels, including transcription, translation, and post-translational processing.
• Inhibitors of AMD1 are being explored as anticancer agents.
• The enzyme is conserved across eukaryotes and prokaryotes, facilitating model organism studies.
• Its activity can be measured using biochemical assays, enabling drug discovery efforts.
• CRISPR-based gene editing allows precise manipulation of AMD1 for functional studies.
Molecular Mechanism of adenosylmethionine decarboxylase activity
Substrate Binding and Catalysis
In simple terms: The enzyme grabs SAM and removes a carboxyl group, turning it into a molecule used to build polyamines.
Adenosylmethionine decarboxylase binds its substrate, S-adenosyl-L-methionine (SAM), and catalyzes the removal of the carboxyl group, releasing CO2 and forming S-adenosylmethioninamine. This reaction requires a pyruvoyl cofactor that is covalently attached to the enzyme. The catalytic mechanism involves the formation of a Schiff base between the pyruvoyl group and the substrate, facilitating decarboxylation.
Autocatalytic Activation
In simple terms: The enzyme activates itself by cutting its own chain to create a special chemical group needed for its function.
Adenosylmethionine decarboxylase is synthesized as an inactive proenzyme that undergoes autocatalytic processing to generate the active enzyme. This processing involves a serinolysis reaction that cleaves the proenzyme into two subunits and forms a pyruvoyl group at the new N-terminus of the alpha subunit. This unique self-activation mechanism is essential for enzymatic activity.
Cofactor Requirements
In simple terms: The enzyme needs a special built-in cofactor to work, which it makes itself.
The pyruvoyl cofactor is essential for the decarboxylation reaction. Unlike many decarboxylases that use pyridoxal phosphate, adenosylmethionine decarboxylase utilizes a pyruvoyl group. This cofactor is formed through an intramolecular rearrangement during autocatalytic processing.
Regulation of Enzyme Activity
In simple terms: The cell controls how much of this enzyme is made and how active it is, to keep polyamine levels balanced.
Mammalian adenosylmethionine decarboxylase is regulated by multiple mechanisms, including transcriptional control, mRNA translation, and rapid degradation of the enzyme. Polyamines themselves can feedback-regulate AMD1 activity and expression. Additionally, the enzyme can be inhibited by specific inhibitors, such as those targeting the pyruvoyl cofactor.
Key Genes Involved in GO:0004014 adenosylmethionine decarboxylase activity
The following genes and proteins are key players in adenosylmethionine decarboxylase activity and related polyamine metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AMD1 | Encodes adenosylmethionine decarboxylase, the enzyme catalyzing the decarboxylation of SAM. | Central to polyamine biosynthesis; target for cancer therapy. |
| ODC1 | Ornithine decarboxylase, first enzyme in polyamine biosynthesis. | Often co-regulated with AMD1; target for inhibitors. |
| SRM | Spermidine synthase, uses decarboxylated SAM to produce spermidine. | Downstream enzyme; potential feedback regulator. |
| SMS | Spermine synthase, uses decarboxylated SAM to produce spermine. | Downstream enzyme; linked to AMD1 activity. |
| SAT1 | Spermidine/spermine N1-acetyltransferase, catabolizes polyamines. | Regulates polyamine pool; interacts with AMD1 pathway. |
| PAOX | Peroxisomal N1-acetyl-spermine/spermidine oxidase, involved in polyamine catabolism. | Affects polyamine homeostasis. |
| SMOX | Spermine oxidase, catabolizes spermine. | Modulates polyamine levels. |
| MAT1A | Methionine adenosyltransferase, synthesizes SAM. | Provides substrate for AMD1. |
| MAT2A | Methionine adenosyltransferase, synthesizes SAM. | Provides substrate for AMD1. |
| MTO1 | Mitochondrial tRNA modification, indirectly linked to polyamine metabolism. | Potential cross-talk. |
| EIF5A | Translation factor activated by spermidine, downstream of polyamines. | Effector of polyamine function. |
| MYC | Oncogene that regulates AMD1 expression. | Links AMD1 to cancer proliferation. |
| MTOR | Kinase that promotes polyamine synthesis. | Regulates AMD1 translation. |
| ATF4 | Stress-responsive transcription factor that can induce AMD1. | Links AMD1 to integrated stress response. |
| HIF1A | Hypoxia-inducible factor, may regulate AMD1 under hypoxia. | Potential role in cancer metabolism. |
| TP53 | Tumor suppressor, may indirectly affect polyamine metabolism. | Loss of p53 alters polyamine pathways. |
| PTEN | Tumor suppressor, loss leads to increased polyamine synthesis. | Links AMD1 to PI3K/AKT pathway. |
| NFKB1 | Transcription factor, regulates inflammatory and polyamine genes. | Potential regulator of AMD1. |
How Is adenosylmethionine decarboxylase activity Regulated?
Adenosylmethionine decarboxylase activity is tightly regulated at multiple levels to maintain polyamine homeostasis. In mammals, AMD1 mRNA translation is stimulated by polyamines through a unique upstream open reading frame (uORF) mechanism, ensuring feedback control. Additionally, mTOR signaling promotes AMD1 translation in response to growth signals. The enzyme is also subject to rapid degradation, with a half-life of less than an hour, allowing quick adjustments to activity. Furthermore, antizyme, a protein induced by polyamines, can inhibit ornithine decarboxylase and affect polyamine levels, indirectly influencing AMD1.
adenosylmethionine decarboxylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AMD1 | Cancer (e.g., prostate, breast) | Knockout or overexpression in cancer cell lines; xenograft models. |
| AMD1 | Alzheimer's disease | Brain-specific knockout or overexpression in mouse models. |
| AMD1 | Metabolic disorders | Liver-specific knockout or overexpression in mice. |
| ODC1 | Cancer | Knockout or inhibitor treatment in cell lines. |
| SRM | Cancer | Knockout or knockdown in cancer cells. |
Cancer
Elevated adenosylmethionine decarboxylase activity and polyamine levels are frequently observed in cancer cells, supporting their rapid proliferation. AMD1 is overexpressed in several cancers, including prostate, breast, and colorectal cancer, and is associated with poor prognosis. Inhibitors of AMD1, such as those targeting the pyruvoyl cofactor, have shown anticancer activity in preclinical models. Therefore, AMD1 is considered a promising therapeutic target [4,7].
Neurodegenerative Diseases
Altered polyamine metabolism has been implicated in neurodegenerative disorders. For instance, adenosylmethionine decarboxylase activity is increased in the brains of Alzheimer's disease patients, suggesting a role in disease pathology. Polyamines can modulate NMDA receptors and oxidative stress, contributing to neuronal dysfunction. Targeting AMD1 may offer neuroprotective strategies.
Metabolic Disorders
Dysregulation of polyamine synthesis, including AMD1 activity, has been linked to metabolic disorders such as obesity and diabetes. Polyamines influence insulin sensitivity and adipogenesis, and AMD1 expression is altered in metabolic tissues. Further research is needed to fully elucidate these connections.
From adenosylmethionine decarboxylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AMD1 knockout inhibit tumor growth? | CRISPR knockout of AMD1 in cancer cell lines and mouse xenografts. |
| What is the effect of a specific point mutation in AMD1 on enzyme activity? | CRISPR point mutation knock-in in cell lines, followed by enzyme assay. |
| How does overexpression of AMD1 affect polyamine levels? | CRISPR-mediated overexpression (e.g., CRISPRa) in cell lines. |
| Can a tagged AMD1 be used to study its localization? | Knock-in of a fluorescent tag (e.g., GFP) at the endogenous locus. |
| What is the role of AMD1 in neuronal function? | Brain-specific knockout or overexpression in mice. |
| Can AMD1 inhibitors be tested in vivo? | Xenograft models with AMD1-overexpressing tumors. |
How to Study the adenosylmethionine decarboxylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiometric CO2 release assay | Enzyme activity by quantifying 14CO2 from labeled SAM. | Kinetic studies and inhibitor screening. |
| HPLC | Decarboxylated SAM production. | Quantification of enzyme activity in cell lysates. |
| Metabolic flux analysis | Flux through polyamine pathway. | Cancer metabolism studies. |
| CRISPR knockout screening | Genes affecting cell fitness under AMD1 inhibition. | Target discovery and synthetic lethality. |
| X-ray crystallography | Three-dimensional structure of AMD1. | Structure-based drug design. |
| Western blot | Protein expression levels of AMD1. | Regulation studies. |
| qRT-PCR | mRNA expression of AMD1. | Transcriptional regulation. |
| Immunofluorescence | Subcellular localization of AMD1. | Cell biology studies. |
Enzyme Activity Assays
Adenosylmethionine decarboxylase activity can be measured using radiometric assays that quantify the release of 14CO2 from labeled SAM. Alternatively, HPLC-based methods can detect the formation of decarboxylated SAM. These assays are essential for characterizing enzyme kinetics and testing inhibitors.
Metabolic Flux Analysis
In silico prediction of metabolic fluxes in cancer cells with altered AMD1 activity can be performed using computational models. This approach integrates genomic and metabolomic data to estimate polyamine pathway fluxes. Experimental validation can be done using stable isotope tracing and mass spectrometry.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to AMD1 inhibitors or regulate polyamine metabolism. Such screens have revealed synthetic lethal interactions and potential combination therapies. Bioinformatics analysis of screening data helps prioritize candidate targets.
Structural Biology
X-ray crystallography and cryo-EM can elucidate the structure of AMD1, including its active site and cofactor binding. These studies inform the design of specific inhibitors. Structural analysis of mutant enzymes can reveal mechanisms of catalysis and regulation.
How CRISPR Can Be Used to Study GO:0004014 adenosylmethionine decarboxylase activity
Knockout
CRISPR knockout of AMD1 can completely abolish adenosylmethionine decarboxylase activity, leading to depleted polyamine levels and growth arrest in many cell types. This model is useful for studying the essentiality of AMD1 and for identifying compensatory pathways. Knockout cell lines can also be used to test the efficacy of AMD1 inhibitors.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions in AMD1 to study catalytic residues or regulatory sites. For example, mutating the active-site serine involved in autocatalytic processing can prevent enzyme activation. Such models help dissect the mechanism of catalysis and regulation.
Knock-in
Knock-in of a tag (e.g., GFP or FLAG) at the endogenous AMD1 locus allows real-time tracking of enzyme expression and localization. This approach preserves endogenous regulatory elements, providing physiological relevance. Tagged AMD1 can be used for immunoprecipitation and proteomics.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase AMD1 levels, leading to elevated polyamine synthesis. Overexpression models are useful for studying the consequences of AMD1 dysregulation, such as oncogenic transformation. They can also be used to test drug resistance mechanisms.
How EDITGENE Supports adenosylmethionine decarboxylase activity Research
Researchers studying adenosylmethionine decarboxylase activity-related genes often need to determine whether a candidate gene is causally involved in polyamine metabolism, cancer progression, or other biological processes. Precise genetic models are essential to establish causality and to validate therapeutic targets. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for adenosylmethionine decarboxylase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AMD1 Knockout HEK293 Cell Line | EDJ-KQ50114 | Human | 262 | Details Get a Quote |
| AMD1 Knockout HeLa Cell Line | EDJ-KQ52605 | Human | 262 | Details Get a Quote |
| AMD1 Knockout A-549 Cell Line | EDJ-KQ61084 | Human | 262 | Details Get a Quote |
| AMD1 Knockout HCT 116 Cell Line | EDJ-KQ69567 | Human | 262 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
Frequently Asked Questions About adenosylmethionine decarboxylase activity
What is adenosylmethionine decarboxylase activity?
Adenosylmethionine decarboxylase activity (GO:0004014) is the enzyme activity that catalyzes the conversion of S-adenosyl-L-methionine to S-adenosylmethioninamine and CO2, a key step in polyamine biosynthesis.
What genes are involved in adenosylmethionine decarboxylase activity?
The primary gene is AMD1, which encodes the enzyme adenosylmethionine decarboxylase. Other genes in the polyamine pathway include ODC1, SRM, and SMS.
What is the role of AMD1 in cancer?
AMD1 is often overexpressed in cancer, leading to elevated polyamine levels that support rapid cell growth. It is a potential therapeutic target.
How is adenosylmethionine decarboxylase activity regulated?
It is regulated at transcriptional, translational, and post-translational levels, including feedback by polyamines and regulation by mTOR signaling.
What diseases are associated with altered adenosylmethionine decarboxylase activity?
Altered activity is linked to cancer, Alzheimer's disease, and metabolic disorders [4,8].
How can I measure adenosylmethionine decarboxylase activity?
Common methods include radiometric assays measuring 14CO2 release and HPLC detection of decarboxylated SAM.
What are the substrates and products of adenosylmethionine decarboxylase?
The substrate is S-adenosyl-L-methionine (SAM), and the products are S-adenosylmethioninamine and CO2.
What is the cofactor required for adenosylmethionine decarboxylase activity?
The enzyme uses a pyruvoyl cofactor, which is formed by autocatalytic processing of the proenzyme.
Can CRISPR be used to study adenosylmethionine decarboxylase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to study AMD1 function and regulation.
What are the potential therapeutic strategies targeting adenosylmethionine decarboxylase?
Inhibitors of AMD1, such as those targeting the pyruvoyl cofactor, are being developed as anticancer agents.
Conclusion
Adenosylmethionine decarboxylase activity (GO:0004014) is a fundamental enzymatic function in polyamine biosynthesis, with critical roles in cell growth, proliferation, and disease. Its dysregulation is implicated in cancer, neurodegeneration, and metabolic disorders, making it an attractive therapeutic target. Advances in CRISPR-based models and biochemical assays continue to unravel its regulation and function, offering new opportunities for drug discovery. EDITGENE's comprehensive services support researchers in dissecting this pathway with precision and efficiency.
References
- 1. Pegg AE. 2009. S-Adenosylmethionine decarboxylase.. Essays Biochem 46:25-45 PMID: 20095968
- 2. Tiburcio AF et al.. 2018. Determination of S-Adenosylmethionine Decarboxylase Activity in Plants.. Methods Mol Biol 1694:123-128 PMID: 29080162
- 3. Persson L. 2009. Polyamine homoeostasis.. Essays Biochem 46:11-24 PMID: 20095967
- 4. Dotsenko O et al.. 2021. In Silico Prediction of Metabolic Fluxes in Cancer Cells with Altered S-adenosylmethionine Decarboxylase Activity.. Cell Biochem Biophys 79(1):37-48 PMID: 33040301
- 5. Bale S et al.. 2010. Structural biology of S-adenosylmethionine decarboxylase.. Amino Acids 38(2):451-60 PMID: 19997761
- 6. Pegg AE et al.. 1988. Regulation of mammalian S-adenosylmethionine decarboxylase.. Adv Enzyme Regul 27:43-55 PMID: 3250232
- 7. Ai Y et al.. 2025. High-Efficiency Discovery and Structure-Activity-Relationship Analysis of Nonsubstrate-Based Covalent Inhibitors of S-Adenosylmethionine Decarboxylase.. J Med Chem 68(15):15483-15494 PMID: 40679143
- 8. Morrison LD et al.. 1993. Brain S-adenosylmethionine decarboxylase activity is increased in Alzheimer's disease.. Neurosci Lett 154(1-2):141-4 PMID: 8361629
